News

Olympia Pharmaceuticals | 503B Outsourcer | 503A Compounding Pharmacy

Market 50/100How we got 50/100Source tierUnclassified sourceTier ceiling50/100Independent sourcesnot recordedPublished score50/100Scored at the ceiling for a unclassified source source — it cannot go higher. The number is the source page’s own score, hard-capped at the tier ceiling; corroboration is recorded but cannot lift a score past that cap. Under 40 a claim goes to review instead of publication. Full methodology →
July 28, 2026↗ source

Olympia Pharmaceuticals, operating as both a 503B FDA-registered outsourcing facility and a 503A compounding pharmacy, has expanded its service offerings to include a wide array of peptide-based therapies. The company provides compounded medications for weight management, longevity, and hormonal health, featuring popular peptides like GLP-1 agonists and regenerative compounds such as BPC-157 and TB-500. Their model emphasizes regulatory compliance, rigorous testing, and nationwide distribution to both clinics and patients.

Related peptides

BPC-157TB-500IpamorelinCJC-1295SermorelinGlutathioneGLP-1LongevityUreaGLP-1 AgonistsCJC 1295 + IpamorelinGLP-1 therapies
We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.